Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TKT May Have Enablement Argument Vs. Amgen's EPO Patents, Judge Says

Executive Summary

Transkaryotic Therapies may have an enablement argument against Amgen's patents for erythropoietin, Judge William Young said during a hearing held March 27-28 in Boston federal court to define claims included in the EPO marketer's patents.

You may also be interested in...



TKT Asks Judge To Limit Amgen's "30 Years" EPO Exclusivity As Trial Begins

Amgen's erythropoietin patents should not translate into 30 years of Epogen exclusivity, Transkaryotic Therapies said in opening arguments May 15 in Boston federal court.

TKT Asks Judge To Limit Amgen's "30 Years" EPO Exclusivity As Trial Begins

Amgen's erythropoietin patents should not translate into 30 years of Epogen exclusivity, Transkaryotic Therapies said in opening arguments May 15 in Boston federal court.

Amgen/TKT EPO

Trial set for May 15 in EPO patent dispute. Amgen claims TKT's gene-activated erythropoietin infringes its Epogen patents (1"The Pink Sheet" April 3, p. 7). Judge William Young will hear the case in Boston federal court

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel